RGC32, also known as C13orf15, is a 137 amino acid protein that localizes to the cytoplasm, as well as to the nucleus and the centrosome. Expressed at high levels in kidney, pancreas and skeletal muscle and at lower levels in brain, heart and placenta, RGC32 functions to modulate the activity of cell cycle-specific kinases, thereby regulating cell cycle progression. Additionally, RGC32 may promote cell cycle arrest at the G2/M phase transition and is thought to inhibit the growth of glioma cells, possibly functioning as a tumor suppressor. Conversely, overexpression of RGC32 may promote cell replication and assist in the pathogenesis of malignancies, suggesting that RGC32 also participates in tumor transformation and progression. RGC32 activity is induced by complement activation and by p53 in response to DNA damage. Multiple isoforms of RGC32 exist as a result of alternative splicing events.

RGC32; Chromosome 13 open reading frame 15; KIAA0564; MGC87338; response gene to complement 32; Response gene to complement 32 protein; RGC 32; RGCC_HUMAN.

Rat,Human,Mouse

IHC,IF,ICC

IHC 1:100-500
IF 1:100-500
ICC 1:100-1:400

15kD

28984

Q9H4X1

https://www.uniprot.org/uniprotkb/Q9H4X1

Cytoplasm. Nucleus. Cytoplasm cytoskeleton centrosome. Note: Cytoplasmic in unstimulated cells. Nuclear after activation by complement. Associated with the centrosome during prometaphase and metaphase.

Detected in brain, heart and liver (at protein level). Highly expressed in liver, skeletal muscle, kidney and pancreas. Detected at lower levels in heart, brain and placenta. Detected in aorta endothelial cells. Overexpressed in colon, breast, prostate, bladder, lung, and ovarian cancer tissues.

KLH conjugated synthetic peptide derived from human RGC32

Rabbit

Polyclonal

IgG

affinity purified by Protein A

Liquid

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.